Pancreatic Cancer Research

ResearcherJohns Hopkins UniversityActive in the last 2 years

Ignace H. J. T. de Hingh

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3491-4268; OpenAlex author ID A5074957985. Sources: OpenAlex.

Their work

Papers
109 (first author 2, last author 5)
Trials
0
Grants
0
Labs led
1
Collaborators
178
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 4 papers · 2016: 9 papers · 2017: 3 papers · 2018: none · 2019: 2 papers · 2020: 7 papers · 2021: 10 papers · 2022: 12 papers · 2023: 13 papers · 2024: 13 papers · 2025: 16 papers · 2026: 16 papers

Papers 50 of 109

  1. Radiofrequency Ablation and Chemotherapy vs Chemotherapy Only in Locally Advanced Pancreatic Cancer: The PELICAN Randomized Clinical Trial. Co-author DOI 10.1001/jamanetworkopen.2026.3861↗
  2. Transcriptome-Based Classification of Resected Pancreatic Ductal Adenocarcinoma Enhances Prognostic Modelling Accuracy of Overall Survival Following Adjuvant T… Co-author DOI 10.1002/ijc.70519↗
  3. Comparing short- and long-term survivors in metastatic pancreatic cancer: Insights into patient and disease profiles impacting systemic therapy outcomes. Co-author DOI 10.1016/j.ejca.2026.116263↗
  4. The impact of age on quality of life, 90-day mortality, adjuvant chemotherapy, and survival after treatment for localized pancreatic cancer: A nationwide analy… Co-author DOI 10.1016/j.ejca.2026.116822↗
  5. Timing of adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma: A nationwide analysis. Co-author DOI 10.1016/j.ejso.2025.111165↗
  6. Preference versus protocol: oncology clinicians' perspectives on central venous access for administration of chemotherapy in pancreatic cancer. Co-author DOI 10.1016/j.esmogo.2026.100311↗
  7. Regional variation for tumour-directed treatment and survival in patients with pancreatic adenocarcinoma: a nationwide population-based analysis. Co-author DOI 10.1016/j.hpb.2025.12.035↗
  8. Contemporary challenges in long-term survival prediction in resected pancreatic ductal adenocarcinoma: a transatlantic multicenter development and validation o… Co-author DOI 10.1016/j.hpb.2026.04.453↗
  9. Surgical outcomes from nationwide implementation of the international best practice for locally advanced pancreatic cancer (PREOPANC-4) study. Co-author DOI 10.1093/bjs/znag075↗
  10. Continuity of care experienced by patients diagnosed with pancreatic cancer: nationwide multicentre study. Co-author DOI 10.1093/bjsopen/zrag033↗
  11. Real-world implementation of a decision aid for treatment decisions in metastatic pancreatic cancer: a prospective multicenter study across expert centers. Co-author DOI 10.1093/oncolo/oyag373↗
  12. Staging Laparoscopy After Neoadjuvant Treatment for Pancreatic Cancer to Prevent Non-Therapeutic Laparotomy: Analysis in the PREOPANC-2 Randomized Trial. Co-author DOI 10.1097/sla.0000000000007025↗
  13. Thromboembolic Events During Perioperative Therapy for Resectable and Borderline Resectable Pancreatic Cancer in the PREOPANC-2 Trial. Co-author DOI 10.1200/jco-25-01935↗
  14. Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18639-1↗
  15. ASO Visual Abstract: Impact of Different Primary Treatment Strategies on Recurrence-Focused Treatment of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1245/s10434-025-18791-8↗
  16. The Value of Stereotactic Radiotherapy After FOLFIRINOX in Patients with Pancreatic Cancer with Vascular Contact-A Nationwide, Retrospective Cohort Study. Co-author DOI 10.3390/cancers18040700↗
  17. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  18. Patterns of disease dissemination and survival in patients with synchronous and metachronous metastatic pancreatic adenocarcinoma: Nationwide population-based … Co-author DOI 10.1016/j.ejca.2025.115385↗
  19. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Co-author DOI 10.1016/j.ejca.2025.116065↗
  20. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  21. Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multice… Co-author DOI 10.1016/s1470-2045(25)00363-8↗
  22. Resectability stages of pancreatic cancer: nationwide reference. Co-author DOI 10.1093/bjs/znaf120↗
  23. Delayed gastric emptying after pancreatic cancer surgery impacts time to start of adjuvant treatment but not overall survival: a post-hoc analysis of the PREOP… Co-author DOI 10.1093/bjs/znaf261↗
  24. Time-varying impact of established prognostic factors in resected pancreatic ductal adenocarcinoma. Co-author DOI 10.1093/jnci/djaf196↗
  25. Evaluation of Short and Long-term Outcomes After Resection in Patients With Locally Advanced Versus (Borderline) Resectable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006289↗
  26. Perineural Invasion is an Important Prognostic Factor in Patients With Radically Resected (R0) and Node-negative (pN0) Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000006320↗
  27. Routine Imaging After Resection of Pancreatic Ductal Adenocarcinoma: Nationwide Utilization and Survival Analysis. Co-author DOI 10.1097/sla.0000000000006772↗
  28. Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial. Co-author DOI 10.1097/sla.0000000000006910↗
  29. Nationwide implementation of the international multidisciplinary best-practice for locally advanced pancreatic cancer (PREOPANC-4): study protocol. Co-author DOI 10.1186/s12885-025-13554-w↗
  30. Patient preferences for pancreatic cancer treatment (PERSEUS): a multicenter discrete choice experiment. Co-author DOI 10.1186/s12955-025-02440-5↗
  31. Computer-Aided Decision Support and 3D Models in Pancreatic Cancer Surgery: A Pilot Study. Co-author DOI 10.3390/jcm14051567↗
  32. Quality of Life Among Patients With Locally Advanced Pancreatic Cancer: A Prospective Nationwide Multicenter Study. Co-author DOI 10.6004/jnccn.2024.7091↗
  33. Implementation of Best Practices in Pancreatic Cancer Care in the Netherlands: A Stepped-Wedge Randomized Clinical Trial. Co-author DOI 10.1001/jamasurg.2023.7872↗
  34. Preoperative chemoradiotherapy but not chemotherapy is associated with reduced risk of postoperative pancreatic fistula after pancreatoduodenectomy for pancrea… Co-author DOI 10.1016/j.surg.2024.01.029↗
  35. Metformin boosts antitumor immunity and improves prognosis in upfront resected pancreatic cancer: an observational study. Co-author DOI 10.1093/jnci/djae070↗
  36. Predicting Long-term Disease-free Survival After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Cohort Study. Co-author DOI 10.1097/sla.0000000000006004↗
  37. Minimum and Optimal CA19-9 Response After Two Months Induction Chemotherapy in Patients With Locally Advanced Pancreatic Cancer: A Nationwide Multicenter Study. Co-author DOI 10.1097/sla.0000000000006021↗
  38. Poor Prognostic Factors in Long-Term Survivors of Resected Pancreatic Ductal Adenocarcinoma: An International, Multicenter Cohort Study. Co-author DOI 10.1097/sla.0000000000006539↗
  39. Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): protocol of an i… Co-author DOI 10.1186/s13063-024-08223-5↗
  40. Correction: Recurrent disease detection after resection of pancreatic ductal adenocarcinoma using a recurrence-focused surveillance strategy (RADAR-PANC): prot… Co-author DOI 10.1186/s13063-024-08295-3↗
  41. Nationwide Use and Outcome of Surgery for Locally Advanced Pancreatic Cancer Following Induction Chemotherapy. Co-author DOI 10.1245/s10434-023-14650-6↗
  42. ASO Author Reflections: Nationwide Experience on Locally Advanced Pancreatic Cancer Surgery After Induction Chemotherapy in the Netherlands: A Stepping Stone f… Co-author DOI 10.1245/s10434-023-14704-9↗
  43. The Value of Biological and Conditional Factors for Staging of Patients with Resectable Pancreatic Cancer Undergoing Upfront Resection: A Nationwide Analysis. Co-author DOI 10.1245/s10434-024-15070-w↗
  44. Prediction of Isolated Local Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Nationwide Study. Co-author DOI 10.1245/s10434-024-15664-4↗
  45. The Difficulty of Detecting Occult Metastases in Patients with Potentially Resectable Pancreatic Cancer: Development and External Validation of a Preoperative … Co-author DOI 10.3390/jcm13061679↗
  46. Serum levels of iCAF-derived osteoglycin predict favorable outcome in pancreatic cancer. Co-author DOI 10.1002/ijc.34276↗
  47. The yield of staging laparoscopy for resectable and borderline resectable pancreatic cancer in the PREOPANC randomized controlled trial. Co-author DOI 10.1016/j.ejso.2022.12.011↗
  48. Population-based impact of COVID-19 on incidence, treatment, and survival of patients with pancreatic cancer. First author DOI 10.1016/j.hpb.2023.04.017↗
  49. Nationwide evaluation of pancreatic cancer networks ten years after the centralization of pancreatic surgery. Co-author DOI 10.1016/j.hpb.2023.07.904↗
  50. Practice variation in venous resection during pancreatoduodenectomy for pancreatic cancer: A nationwide cohort study. Co-author DOI 10.1016/j.surg.2023.06.012↗

Closest collaborators

The 25 strongest of 178 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marc G. Besselink · 88 shared papers, 2014–2026 · strength 11.34
  2. Hjalmar C. van Santvoort · 60 shared papers, 2014–2026 · strength 8.17
  3. Izaak Quintus Molenaar · 62 shared papers, 2014–2026 · strength 7.61
  4. Bas Groot Koerkamp · 51 shared papers, 2017–2026 · strength 7.10
  5. Martijn W.J. Stommel · 46 shared papers, 2020–2026 · strength 6.74
  6. Bert A. Bonsing · 51 shared papers, 2014–2026 · strength 6.70
  7. Vincent Erwin de Meijer · 43 shared papers, 2020–2026 · strength 6.37
  8. Johanna W. Wilmink · 41 shared papers, 2016–2026 · strength 6.03
  9. Judith de Vos‐Geelen · 38 shared papers, 2016–2026 · strength 5.64
  10. Casper H.J. van Eijck · 44 shared papers, 2014–2026 · strength 5.53
  11. Sebastiaan Festen · 37 shared papers, 2016–2026 · strength 5.18
  12. Lois A. Daamen · 31 shared papers, 2021–2026 · strength 4.75
  13. Marjolein Y.V. Homs · 25 shared papers, 2020–2026 · strength 4.13
  14. Geert Kazemier M · 26 shared papers, 2016–2026 · strength 3.69
  15. Gijs A. Patijn · 29 shared papers, 2016–2026 · strength 3.67
  16. Hanneke W.M. van Laarhoven · 25 shared papers, 2015–2026 · strength 3.36
  17. Martijn Intven · 20 shared papers, 2021–2026 · strength 3.05
  18. Lydia G. van der Geest · 20 shared papers, 2016–2026 · strength 2.88
  19. Geertjan van Tienhoven · 21 shared papers, 2016–2026 · strength 2.67
  20. Vincent B. Nieuwenhuijs · 18 shared papers, 2020–2026 · strength 2.48
  21. Iris W.J.M. van Goor · 14 shared papers, 2021–2026 · strength 2.22
  22. Robert C. Verdonk · 14 shared papers, 2022–2026 · strength 2.15
  23. Lodewijk A.A. Brosens · 16 shared papers, 2014–2026 · strength 2.11
  24. Thijs J. Schouten · 14 shared papers, 2021–2026 · strength 2.06
  25. J. Sven D. Mieog · 12 shared papers, 2021–2026 · strength 1.80

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.